Hengrui Pharma(SH:600276) Ge Long Hui·2025-07-09 07:03Group 1 - The core viewpoint of the article highlights the resilience of the innovative drug sector in the face of potential tariff threats from the U.S. government, with significant stock price increases observed in various companies [1][5] - Notable stock performances include Heng Rui Pharmaceutical, which surged over 18% to reach a new high, and other companies like Boan Biotechnology and Tigermed, which rose by 10.57% and 6.18% respectively [1][5] - The overall A-share market saw an increase of over 7%, indicating strong investor confidence in the innovative drug sector despite external pressures [1] Group 2 - The article reports that several ETFs tracking innovative drugs also experienced gains, with the Cathay Innovative Drug ETF rising by 1.83% and the Huatai-PB Innovative Drug ETF increasing by 1.61% [1][3] - Year-to-date performance of various ETFs shows significant growth, with the Hong Kong Stock Connect Innovative Drug ETF up by 66.23% [10] - The innovative drug sector has been a top performer this year, with multiple indices reflecting over 60% growth, indicating a strong market trend [9][10] Group 3 - The article mentions that Heng Rui Pharmaceutical received approval for clinical trials of its SHR-2173 injection, which could enhance its market position [5] - Citigroup has initiated a buy rating for Heng Rui Pharmaceutical's H-shares with a target price of 134 HKD, reflecting confidence in the company's leadership in the pharmaceutical industry [5] - The article also notes significant net inflows into ETFs tracking innovative drugs, with 10.9 billion CNY into the Hong Kong Stock Connect Innovative Drug ETF last week [7]